Lundbeck delivers at the top-end of guidance and momentum is expected to continue in 2011
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) announces 2010 results, which meet all financial expectations. Full year revenue was DKK 14,765 million and increased 7% compared to 2009, driven by a positive development in all regions.
Sanofi Pasteur and International Vaccine Institute Partner against Dengue
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that it is partnering with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI).
ONGLYZA™ US label update regarding use in renally impaired adults with type 2 diabetes
- Details
- Category: AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced that the US Food and Drug Administration (FDA) has approved the inclusion of data from two clinical studies in an update to the ONGLYZA (saxagliptin) US Prescribing Information for adult type 2 diabetes patients.
Forest Laboratories to Acquire Clinical Data, Inc.
- Details
- Category: Financial
Forest Laboratories, Inc. (Forest) (NYSE: FRX) and Clinical Data, Inc. (Clinical Data) (NASDAQ: CLDA) have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics,
Novartis gains positive CHMP opinion for Rasilamlo(TM)
- Details
- Category: Novartis
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Rasilamlo(TM) (aliskiren and amlodipine) to treat high blood pressure patients not adequately controlled by either aliskiren or amlodipine alone.
Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Genzyme Corporation (NASDAQ: GENZ) have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion.
Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) reported fourth-quarter 2010 results that reflect increasing supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta), revenue growth across all major product lines, and reductions in operating expenses.
More Pharma News ...
- Pfēnex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement
- Lilly Marks Major Milestone for Mirror Portfolio
- First African country introduces GSK's pneumococcal vaccine
- New AVERROES Data Demonstrate Investigational Apixaban Superior to Aspirin
- Elan and Boehringer Ingelheim Announce Development and Manufacturing Agreement
- Sanofi-aventis' fourth-quarter and full-year net sales
- Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET